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Objectives. The purpose of this study was to determine the time 
course of the appearance ofabnormal Q waves on the electrocar- 
diogram (ECG) over the first 6 h of symptoms of myocardial 
infarction and to determine what implications, if any, such Q 
waves have for the efficacy of thrombolytic therapy. 
Background. Severe myocardial ischemia can produce early 
QRS changes in the absence of infarction. Abnormal Q waves on 
the baseline ECG may not be an accurate marker of irreversibly 
injured myocardium. 
Methods. Data from 695 patients who had no past history, of 
myocardial infarction and whose admission ECG allowed predic- 
tion of myocardial infarct size in the absence of thrombolytic 
therapy (Aldrich score) were pooled from four prospective trials of 
thrombolytic therapy. The presence and number of abnormal Q 
waves on each patient's initial ECG were recorded. Four hundred 
thirty-six patients had left ventricular infarct size measured using 
quantitative thallium-201 tomography a mean (-+SD) of 52 -+ 43 
days after admission. 
Results. Of patients admitted within 1 h of symptoms, 53% had 
abnormal Q waves on the initial ECG. Both predicted and final 
infarct size were larger in patients with abnormal Q waves on the 
initial ECG independent of the duration of symptoms before 
therapy (p < 0.001). Despite this finding, the presence of abnor- 
mal Q waves on the admission ECG did not eliminate the effect of 
thrombolytic therapy on reducing final infarct size (p < 0.0001). 
Conclusions. Abnormal Q waves are a common finding early in 
the course of acute myocardial infarction. However, there is no 
evidence that abnormal Qwaves are associated with less benefit in 
terms of reduction of infarct size after thrombolytic therapy. 
(J Am Coil Cardiol 1995;25:1084-8) 
Myocardial infarction is often associated with the loss of R 
wave voltage in the electrocardiographic (ECG) leads corre- 
sponding to the affected area. The magnitude and distribution 
of QRS changes observed on an ECG performed several days 
after infarction, including the resulting abnormal Q waves, 
have been shown to be an accurate indicator of myocardial 
infarct size in patients not undergoing thrombolytic therapy 
(1). In contrast, such changes in the QRS complex have not 
been found to correlate well with ejection fraction, regional 
wall motion abnormalities or perfusion defect size in patients 
who have received thrombolytic therapy for acute myocardial 
infarction (2). 
Little is known about the time course or importance of 
abnormal Q waves present during the first few hours of 
myocardial infarction and what implications, if any, abnormal 
Q waves on the admission ECG have for the effectiveness of 
thrombolytic therapy. Transient changes in R wave amplitude, 
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probably resulting from ischemia-induced intramyocardial 
conduction delays, have been observed uring ischemia in- 
duced during coronary angioplasty as well as in experimental 
animal models of ischemia (3-6). If an ischemia-induced 
conduction delay resulted in a shift in early electrical forces 
that would normally be recorded as an R wave to later in the 
QRS complex, then opposing unaffected electrical forces might 
result in the inscription of abnormal Q waves (7). Thus, Q 
waves present early in the course of acute myocardial infarc- 
tion may not represent irreversibly damaged myocardium. We 
therefore hypothesized that abnormal Q waves on the admis- 
sion ECG may not be a reliable marker of reduced potential 
for myocardial salvage with thrombolytic therapy. 
Methods  
Patients. Data from patients in four studies of thrombo- 
lytic therapy were combined for analysis: the Western Wash- 
ington Randomized Trial of Intracoronary Streptokinase in
Acute Myocardial Infarction (8), Western Washington Intra- 
venous Streptokinase in Acute Myocardial Infarction Ran- 
domized Trial (9), Western Washington Myocardial Infarction 
Registry and Emergency Department Tissue Plasminogen 
Activator Treatment Trial (10) and Myocardial Infarction 
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Table 1. Definition of Abnormal Q Waves 
ECG Lead Criteria ECG Lead Criteria 
1 _>30 ms V~ Any 
II ->30 ms V 3 Any 
aVL _->30 ms V 4 220 ms 
aVF _->30 ms V.~ 230 ms 
V~ Any V~, 230 ms 
ECG = electrocardiographic. 
Triage and Intervention Pre-Hospital Trial (11). All study 
patients presented with symptoms of acute myocardial infarc- 
tion and met standard clinical and ECG eligibility criteria for 
thrombolytic therapy. In the older two studies (8,9), patients 
were randomized to undergo thrombolysis with streptokinase 
or standard therapy for acute myocardial infarction without 
thrombolysis (9). In the two more recent rials (10,11) recom- 
binant issue-type plasminogen activator ( t-PA) was utilized in 
all patients. All patients with a past history of myocardial 
infarction and those in whom the Aldrich score (see Electro- 
cardiograms) could not be calculated because the initial ECG 
had bundle branch block or left ventricular hypertrophy were 
excluded from the analysis. Data on age, gender, duration of 
chest pain before thrombolytic therapy, systolic blood pressure 
and heart rate were gathered prospectively and were available 
for each patient. 
Electrocardiograms. The initial ECGs for all eligible pa- 
tients were reviewed by investigators who were unaware of 
clinical presentation, hospital course and radionuclidc infarct 
size results. The location of each myocardial infarction was 
defined on the basis of the ECG leads with the greatest 
magnitude of ST segment elevation and was recorded as 
anterior (leads V~ to V4) or inferior (leads II, III, aVF). The 
number of abnormal Q waves, as defined by Selvester et al. (1) 
(Table 1), on the initial ECG was determined for each patient. 
In addition, the presence or absence and magnitude of ST 
segment elevation and depression were recorded. The magni- 
tude and location of ST segment elevation were used to 
estimate the left ventricular infarct size that each patient was at 
risk for should thrombolytic therapy not be given. This estima- 
tion, the Aldrich score, is calculated by the following formulas: 
for anterior infarction, 3[1.5(number of leads with ST segment 
elevation) - 0.4]; and for inferior infarction, 3[0.6(sum of ST 
segment elevation leads II, Ill, aVF) + 2.0] (12). 
Radionuclide studies. Rest quantitative thallium-201 to- 
mographic imaging was performed a mean (+SD) of 52 _+ 43 
days after hospital discharge as part of each of the original 
protocols at a single central nuclear medicine laboratory. The 
results were analyzed by investigators who had no knowledge 
of the therapy and hospital course. Quantitative infarct size 
was measured as a percent of the left ventricle and performed 
using image acquisition and processing methods that have 
been previously reported and validated (13). 
Statistical analysis, Two-tailed t and chi-square tests were 
used to assess the statistical significance of observed iffer- 
ences in baseline clinical variables of patients with and without 
Table 2. Baseline Patient Characteristics 
No 
Abnormal Abnormal 
Q Waves Q Waves 
(n = 337) (n : 358) p Value 
Male (%) 81.3 88.2 0.17 
Age (yr) 56 _+ 10 57 + 1 0.21 
Initial heart rate (beats/min) 71 _+ 16 77 -+ lg <0.001 
Systolic blood pressure on 134 _+ 27 138 _+ 26 0.09 
admission (mm Hg) 
Time from symptom onset o 2.7 + 1.5 3.0 _+ 1,8 0.02 
treatment (h) 
Anterior infarct location (%) 21.7 51.4 <0.001 
Sum of ST segment elevation 8.4 + 6,2 11.0 _+ 8.5 <0.001 
(mm) 
Sum of ST segment depression 7.1 _+ 6.3 5.5 +_ 5.5 <0.001 
(mm) 
No. of abnormal Q waves 0 2.5 -+ 1.3 <0.001 
Aldrich score (% left ventricle) 17.8 _+ 8.5 20.0 + 8.7 <0.001 
Data presented are mean value _+ SD, unless otherwise indicated. 
abnormal Q waves on the initial ECG. Analysis of variance was 
used to determine the statistical significance of the effects of 
time to therapy and the number of abnormal Q waves on 
infarct size. 
Resu l ts  
Baseline patient characteristics. Six hundred ninety-five of 
the 1,138 patients enrolled in the four studies met clinical and 
ECG criteria for study. Reasons for exclusion of the other 443 
patients included previous myocardial infarction in 293 (26%) 
and ECG abnormalities precluding calculation of the Aldrich 
score in 150 (13%). Baseline characteristics of patients with 
and without abnormal Q waves on the initial ECG are shown 
in Table 2. Patients with abnormal Q waves had a higher initial 
heart rate, were more likely to have an anterior infarction, had 
greater ST segment elevation, less ST segment depression and 
a higher predicted infarct size according to Aldrich score. 
Abnormal Q waves on initial ECG. Table 3 shows the 
proportion of patients with abnormal Q waves by time from 
symptom onset to initial ECG. Over half (53%) of patients 
seen within the first hour of symptoms had abnormal Q waves 
on their initial ECG. Overall, the correlation between duration 
of symptoms before admission and number of abnormal Q 
waves on the initial ECG was poor (r = 0.11). 
Table 3. Presence of Abnormal Q Waves on 
Initial Electrocardiogram 
Number of Abnormal Q Waves 
Time to 
Admission 0 l-2 >2 
<l h 90 (47%) 58 (30%) 43 (23%) 
1-2 h 133 (50%) 76 (28%) 58 (22%) 
2-4 h 77 (45%) 49 (29%) 44 (26%) 
>4 h 14 (40%) 8 (23%) 13 (37%) 
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Figure 1. The Aldrich score, predicted infarct size (% left ventricle) 
were thrombolytic therapy not given, is plotted as a function of 
duration of symptoms before thrombolytic therapy and number of 
abnormal Q waves on the initial electrocardiogram (ECG) for 695 
paticnts. By analysis of variance, there was no difference in predicted 
infarct size as a function of duration of symptoms before thrombolytic 
therapy (p - 0.25). The Aldrich score was higher the more Q waves 
there were present on the initial ECG (p < 0.0001). 
Predicted and final infarct size. In Figure 1, predicted 
myocardial infarct size had thrombolytic therapy not been 
given, the Aldrich score, is plotted as a function of time to 
treatment and number of abnormal Q waves on the initial 
ECG. There was no significant relation between duration of 
symptoms before presentation and predicted infarct size, sug- 
gesting that if thrombolytic therapy had not been administered 
there would be no difference in infarct size in these patients as 
a function of duration of symptoms before hospital admission. 
The same finding, no association between predicted infarct size 
and time to admission, was observed when the analysis was 
limited to the subset of 339 patients who received thrombolytic 
therapy and had final infarct size measured by thallium tomog- 
raphy. 
In Figure 2, final infarct size measured by rest thallium- 
201 tomography replaces predicted infarct size on the z axis. 
Unlike predicted infarct size, in which there was no relation to 
symptom duration, final infarct size was larger in patients 
treated after a longer duration of symptoms. The largest 
infarcts were seen in patients randomized not to receive 
thrombolytic therapy. The presence of abnormal Q waves on 
the initial ECG was associated with a larger predicted infarct 
size (Fig. 1, p = 0.008) and a larger final infarct size (Fig. 2, p < 
0.0001) independent of duration of symptoms before initiation 
of therapy. Despite this finding, the presence of abnormal Q 
waves on the admission ECG did not eliminate the association 
between a shorter duration of symptoms before thrombolytic 
therapy and smaller final thallium infarct size (p < 0.0001). 
Figure 2. Final infarct size, as measured by quantitative thallium-201 
(TI-20I) tomography (% left ventricle), is plotted as a function of 
duration of symptoms before thrombolytic therapy and number of 
abnormal Q waves on the initial electrocardiogram (ECG) for 436 
patients. By analysis of variance, final infarct size was smaller the 
carlier thrombolytic therapy was given regardless of whether abnormal 
Q waves were present on the initial ECG (p < 0.0001). Abnormal Q 
waves were associated with larger infarct size when duration of 
symptoms before initiation of therapy was taken into account (p < 
o.oool). 
Whether there were no, one to two or more than two abnormal 
Q waves on the initial ECG, final infarct size was smallest in 
patients treated 0 to 2 h after symptom onset, with progres- 
sively larger infarcts in patients treated later and in those who 
did not receive thrombolytic therapy. The largest mean final 
infarct size was measured in patients with more than two 
abnormal Q waves who did not receive thrombolytic therapy 
(22.5% of the left ventricle). Patients with the same number of 
abnormal Q waves on their initial ECG treated at 0 to 2 h after 
symptom onset had a final infarct size of only 10.2%. 
Discuss ion  
Origin of early Q waves. Reversible acute myocardial 
ischemia has been shown to produce R wave voltage changes 
on the ECG, probably as a result of intramyocardial conduc- 
tion delays in the ischemic zone of myocardium (3-6). 
Selvester et al. (7) postulated that proximal or middle occlu- 
sions of the left anterior descending coronary artery produce 
delayed depolarization of myocardium normally activated by 
the septal and anterior fascicles of the left bundle branch and 
result in acute reversible R wave diminution or Q wave 
formation in anterior precordial leads. More distal left anterior 
descending coronary artery occlusions are postulated to result 
in conduction delays localized to the apical portion of the 
anteroseptal wall (leads V 4 to V6) and delayed right septal 
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activation, resulting in augmentation of the R wave in the 
anterior precordial leads. 
We observed abnormal Q waves on the initial ECG more 
commonly in patients with anterior infarction and in those with 
greater ST segment elevation (i.e., in patients with larger areas 
at risk). These findings are consistent with the postulate that 
acute ischemia in regions upplied by the proximal portion of 
the left anterior descending coronary artery can cause local 
intramyocardial conduction delays in the regions of the inser- 
tion of the specialized conduction system, resulting in early Q 
wave formation. On the basis of these observations, we postu- 
lated that occlusion of arteries upplying large areas of myo- 
cardium, especially in the anterior and septal walls of the left 
ventricle, may be more likely to be associated with delayed 
activation of the ischemic zone and thus the development of
abnormal Q waves within the first hour of ischemia. 
Development ofabnormal Q waves can occur very early. In 
the present study, over half (53%) of all patients admitted 
within the first hour of symptoms had abnormal Q waves on 
the ECG. The percent of patients with abnormal Q waves did 
not increase appreciably over the next 6 h. This suggests that 
factors present very early after arterial occlusion, such as the 
amount and location of myocardium served by the affected 
artery, determine whether early abnormal Q waves will de- 
velop. If abnormal Q waves observed in this time frame were 
primarily markers of irreversible infarction, then one would 
expect a significant increase in the proportion of patients with 
abnormal Q waves as the duration of symptoms increased and 
ischemic myocardium became irreversibly infarcted, an associ- 
ation we did not observe. 
Impact of early abnormal Q waves on efficacy of thrombo- 
lytic therapy. The presence of abnormal Q waves on the 
admitting ECG was not associated with a lack of benefit from 
thrombolytic therapy. Neither the presence of one to two nor 
more than two abnormal Q waves eliminated the finding of 
smaller final infarct size in patients with versus without hrom- 
bolytic therapy or those treated after a longer duration of 
symptoms. This finding could not be explained by the possibil- 
ity that patients with abnormal Q waves who received early 
thrombolytic therapy had less myocardium at risk. The pre- 
dicted infarct size before therapy (Aldrich score) showed no 
significant trend as a function of duration of symptoms before 
treatment whether or not abnormal Q waves were present on 
the admission ECG. 
Patients with abnormal Q waves on the admitting ECG had 
a larger predicted infarct size before thrombolytic therapy and 
a larger final infarct size after treatment than those without 
abnormal Q waves on the initial ECG. This is in part due to the 
overrepresentation of anterior infarction in patients with an 
abnormal Q wave but is also the result of abnormal Q waves 
being a marker for larger areas of myocardium atrisk. Finally, 
we cannot exclude the fact that in some patients, abnormal Q 
waves represent irreversibly infarcted myocardium, not just 
reversible conduction abnormalities. Thus, abnormal Q waves 
on the initial ECG are a marker for larger infarcts but do not 
preclude significant limitation of infarct size in many patients 
treated with thrombolytic therapy. 
Study limitations. A limitation of the present study is that 
a substantial proportion (37%) of patients in the four trials 
otherwise ligible for study did not have radionuclide studies, 
and thus the findings in our select cohort with infarct size 
measurements may not be representative of the excluded 
patients. Follow-up studies were not available for two main 
reasons: either patients died before the scheduled follow-up or 
they refused the study, usually because they lived too far from 
the core laboratory. A comparison of patients not included 
versus those included in this cohort reveals no significant 
difference in the number of abnormal Q waves (1.3 ___ 1.6 vs. 
1.3 _+ 1.5, respectively, p -- 0.76) or predicted infarct size 
(19.7 ___ 8.3 vs. 18.7 _+ 8.5, p = 0.21), but the excluded patients 
were treated after a significantly longer duration of symptoms 
than those who were included (194 ___ 103 vs. 143 _+ 86 rain, 
p < 0.0001). Because these patients were treated later, and 
many of the deaths probably represent failure of thrombolytic 
therapy and therefore larger final infarct size, one would 
expect hat their exclusion would cause an underestimation f 
final infarct size predominantly in patients treated relatively 
late after symptom onset. If these patients, who had the same 
number of abnormal Q waves as those with final infarct size 
measurements, had been included in the analysis, an even 
more prominent treatment effect of early therapy might have 
been observed (i.e., an even greater difference in final infarct 
size between patients treated early versus late, independent of
the presence of abnormal Q waves on the admitting ECG). 
Another potential limitation of this study is the use of the 
Aldrich score, an ECG-derived measurement, to estimate 
infarct size before thrombolytic therapy. Direct measurement 
of the myocardium at risk using thallium or technetium 
sestamibi would probably have given a more accurate measure- 
ment of predicted infarct size (14). However, the Aldrich score 
has been shown to have a highly significant correlation with 
final infarct size in patients not receiving thrombolytic therapy 
(12,15). In our study patients, we showed that mean predicted 
final infarct size were thrombolytic therapy not given was 
unaffected by duration of symptoms before therapy; therefore 
the Aldrich score was adequate for our purpose. However, the 
Aldrich score probably does not have a high enough correla- 
tion coefficient with final infarct size to be used as a specific 
measure of myocardium at risk for the determination of 
myocardial salvage in individual patients. 
Finally, the use of a single rest tomographic thallium image 
acquired immediately after injection may lead to overestima- 
tion of myocardial infarct size in some patients because of poor 
thallium uptake in chronically ischemic but viable myocardium. 
Two aspects of the protocol would minimize this effect: First, 
these were rest injections, therefore liminating any effects of 
preceding exercise-induced relative hypoperfusion. Second, 
because of the mean delay of 8 weeks after infarction, overes- 
timation of infarct size as a result of rest ischemia in peri- 
infarct regions is significantly reduced whether or not patients 
are initially treated with thrombolytic therapy (16,17). We 
1088 RAITT ET AL. JACC Vol. 25, No. 5 
ABNORMAL Q WAVES AND INFARCT SIZE April 1995:1084-8 
would thus expect minimal overestimation f infarct size and, 
furthermore, would expect any such errors to be randomly 
distributed across the patient groupings. Specifically, it is 
unlikely that such a false overestimation f infarct size would 
occur in patients as a function of either the duration of 
symptoms before therapy or the presence or absence of 
abnormal Q waves on the initial ECG. 
Clinical implications. In the late phase after myocardial 
infarction, abnormal Q waves often represent infarcted myo- 
cardium (1). It is therefore not unreasonable to assume that 
many clinicians interpret an abnormal Q wave on the admitting 
ECG in a patient with suspected acute myocardial infarction to 
be evidence of late presentation, signifying little potential for 
myocardial salvage. Because of this, many otherwise suitable 
patients may not be offered early reperfusion therapy. The 
findings of the present study suggest hat Q waves are a poor 
predictor of symptom duration; -50% of patients een within 
1 h of symptom onset had abnormal Q waves on the admitting 
ECG. Furthermore, our findings how that abnormal Q waves 
on the admitting ECG identify patients with a greater extent of 
myocardium at risk and that these patients have substantial 
myocardial salvage after treatment with thrombolytic therapy. 
We thank all of the physicians and nurses who participated in the thrombolytic 
therapy studies that formed the basis of this study, as well as Susan Shattuc, MS 
for preparation of the illustrations. 
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